Telix Pharmaceuticals (NASDAQ:TLX) Sets New 52-Week Low – Should You Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX) shares hit a new 52-week low during trading on Tuesday . The stock traded as low as $7.12 and last traded at $7.13, with a volume of 55741 shares. The stock had previously closed at $7.43.

Analyst Upgrades and Downgrades

TLX has been the subject of a number of research reports. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Canaccord Genuity Group raised shares of Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. Wall Street Zen raised shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 23rd. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday, January 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Stock Performance

The firm has a 50 day moving average price of $8.29 and a two-hundred day moving average price of $9.94.

Institutional Investors Weigh In On Telix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pier Capital LLC acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $3,037,000. Blair William & Co. IL acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth $217,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $297,000. Millennium Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the 3rd quarter valued at $1,883,000. Finally, Lazard Asset Management LLC bought a new stake in Telix Pharmaceuticals in the third quarter worth $1,097,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.